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Abstract
Background: The precise role of capsule endoscopy in the diagnostic algorithm of obscure
gastrointestinal bleeding has yet to be determined. Despite the higher diagnostic yield of capsule
endoscopy, the actual impact on clinical outcome remains poorly defined. The aim of this study was
to evaluate the follow-up results of patients with obscure gastrointestinal bleeding to determine
which management strategies after capsule endoscopy reduced rebleeding.
Methods: All patients in whom the cause of obscure gastrointestinal bleeding was investigated
between May 2004 and March 2007 were studied retrospectively. We evaluated the clinical
outcome of patients with obscure gastrointestinal bleeding after capsule endoscopy using the
rebleeding rate as the primary outcome.
Results:  Seventy-seven patients with obscure gastrointestinal bleeding underwent capsule
endoscopy. Capsule endoscopy identified clinically significant findings that were thought to be the
sources of obscure gastrointestinal bleeding in 58.4% of the patients. The overall rebleeding rate
was 36.4%. The rebleeding rate was significantly higher among patients with insignificant findings
than among those with significant findings (p = 0.036). Among the patients in whom capsule
endoscopy produced significant findings, the rebleeding rate of the patients who underwent
therapeutic interventions was significantly lower than that in those who did not undergo
intervention (9.5% vs 40.0%, p = 0.046).
Conclusion:  Follow-up and further aggressive interventions are necessary for patients with
obscure gastrointestinal bleeding and significant capsule endoscopy findings to reduce the chance
of rebleeding.
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Background
Obscure gastrointestinal bleeding (OGIB) is a common
problem encountered by gastroenterologists. OGIB is
defined as bleeding of unknown origin that persists or
recurs after a negative initial evaluation [1], and accounts
for approximately 5% of all gastrointestinal (GI) bleeding
[2]. Many cases of OGIB originate in the small bowel,
where the source of bleeding can be difficult to detect.
Capsule endoscopy (CE) has revolutionized the evalua-
tion of OGIB [3,4]. CE is now a well-accepted non-inva-
sive modality for evaluating diseases of the small intestine
[4-7]. CE has been shown to be superior to push enteros-
copy [8,9], small bowel follow-through [10], and com-
puted tomography [11-13] for detecting bleeding lesions
in the small intestine. Most published studies on CE have
focused on the diagnostic yield, although a few have
focused on clinical outcome – including the rebleeding
rate of patients after CE examination [14,15]. One study
suggested that the influence of CE on clinical outcome
was rather low despite the high diagnostic yield [16]. Data
on whether CE affects patient outcome are sparse. CE can
reveal various findings of the small bowel, but no specific
guidelines exist for the management of lesions detected by
CE. Whether follow-up and further aggressive interven-
tions are necessary for patients after CE remains contro-
versial. The aim of this study was to evaluate the follow-
up results of patients with OGIB who underwent CE to
determine which management strategies after CE reduced
rebleeding.
Methods
All patients who were referred to the Kanto Medical
Center NTT EC to undergo CE for the investigation of
OGIB between May 2004 and March 2007 were evaluated
retrospectively. All of the patients had visible passage of
blood or positive fecal occult blood testing with a drop in
hemoglobin. Most of the patients had undergone a total
colonoscopy, gastroscopy, and small bowel follow-
through examination prior to undergoing CE. Written
informed consent to the CE procedure was obtained from
all the patients. The exclusion criteria were a suspected
small bowel obstruction, stricture, swallowing disorders,
pacemaker implantation, and pregnancy.
All videos were reviewed using the PillCam SB capsule
endoscopy system (Given Imaging Ltd., Israel). CE was
performed after a 12-hour fasting period. Fluid and light
meals were allowed 2 and 4 hours after capsule swallow-
ing. The patients were free to leave the hospital, with
instructions to return within the 8-hour study period to
have the data recorder removed. The recorded digital
information was downloaded from the recorder into the
computer and the images were analyzed using the propri-
etary RAPID software. All CE images were reviewed by two
experienced gastroenterologists. The CE findings were
classified as either clinically significant or clinically insig-
nificant findings. Examples of clinically significant find-
ings included ulcers, angiodysplasias, tumors, bleeding
without identifiable lesion, or Crohn's disease. Examples
of clinically insignificant findings include erosions, small
ulcers, red spots, small polyps, or negative findings. The
definitions for clinically significant or clinically insignifi-
cant findings have been standardized at our institution.
Significant findings were defined as the presence of CE
findings that might account for the clinical bleeding.
Clinical and follow-up data were collected from a review
of the patients' records and by contacting the referring
physicians. Follow-up data collected included the clinical
management of OGIB, episodes of rebleeding after CE,
and the length of the follow-up period. Rebleeding was
defined as the visible passage of blood or positive fecal
occult blood testing with a drop in hemoglobin after the
CE examination.
Statistical analysis
The results were presented as the mean ± standard devia-
tion for quantitative data or a frequency (percentage) for
categorical data. Data were analyzed using a chi-square
test a Yates chi square test or a Fisher's exact test as appro-
priate. A p value of less than 0.05 was considered statisti-
cally significant.
Ethical consideration
This study was carried out in accordance with the Declara-
tion of Helsinki (1989). Ethical permission was granted
by the Kanto Medical Center NTT EC, Tokyo, Japan, Ethics
Committee. Written informed consent was obtained from
all patients for their involvement in this study.
Results
All the CE examinations were performed without any
complications. None of the patients developed intestinal
obstruction during the examination and none required
endoscopic or surgical removal of the capsule. A total of
77 patients with OGIB whose follow-up data were availa-
ble had undergone CE, and their demographic data are
shown in Table 1. In 52 of the 77 (67.5%) patients, the
capsule passed into the cecum within the recording time;
in the remaining 25 (32.5%) patients, the capsule was
spontaneously eliminated within 2 weeks after the CE.
The mean follow-up period was 11.6 months (range: 5–
34 months) after the CE examination. The mode of pres-
entation was overt bleeding in 60 (77.9%) patients and
occult bleeding in 17 (22.1%) patients. The mean lowest
hemoglobin concentration was 7.7 ± 2.9 g/dl (range: 3.5–
17.5 g/dl). Forty-one (53.2%) patients required a transfu-
sion of packed red blood cells for the treatment of anemia
as a result of GI bleeding.BMC Gastroenterology 2008, 8:12 http://www.biomedcentral.com/1471-230X/8/12
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The details of the CE finding in the 77 patients are listed
in Table 2. CE identified clinically significant findings that
were thought to be the sources of OGIB in 45 (58.4%)
patients. On the other hand, CE showed insignificant
findings in 32 (41.6%) patients. Small bowel ulcers were
the most common finding. The second most common
finding was small bowel angiodysplasia.
Twenty-eight (36.4%) patients experienced rebleeding
during the follow-up period. Most of the rebleeding
occurred within the first 6 months after CE, and the mean
interval between the rebleeding and the CE examination
was 5.7 months. During the follow-up period, 12 of the
45 (26.7 %) patients with significant findings developed
clinical rebleeding. On the other hand, 16 of the 32 (50.0
%) patients with insignificant findings developed clinical
rebleeding. The probability of rebleeding was significantly
higher among the patients with insignificant findings
than among those with significant findings (p = 0.036).
In total, 50 of the 77 (64.9 %) patients underwent further
examinations and interventions after the CE; these exam-
inations included endoscopic, surgical, radiographic, and
drug therapy. Of the 50 patients who underwent further
examinations and interventions, 25 patients underwent
therapeutic interventions. Therapeutic interventions
included endoscopic cautery, surgical resection, angio-
graphic embolization, and specific drug therapy, such as
the use of mesalazine for the treatment of Crohn's disease.
In this study, we defined nonsteroidal anti-inflammatory
drugs (NSAIDs) withdrawal for NSAIDs-induced enterop-
athy as a specific drug therapy. Thirty of the 45 (66.7 %)
patients with significant findings underwent further inter-
ventions; of these patients, 21 (70.0 %) underwent thera-
peutic interventions. Among the patients with significant
CE findings, the rebleeding rate of the patients with ther-
apeutic intervention was significantly lower than that of
those without intervention (9.5% vs 40.0%, p = 0.046).
On the other hand, 20 of the 32 (62.5 %) patients with
insignificant findings underwent further interventions
and 4 of these 20 (20.0%) patients underwent therapeutic
interventions. The rebleeding rate between the patients
who did and did not undergo intervention was not signif-
icantly different. The results are presented in Figure 1.
Twenty-seven patients did not undergo further interven-
tion after CE examination. The main reasons for not
undergoing further examinations and interventions were
the CE findings were too small to justify further interven-
tions (n = 10), the absence of clinical rebleeding for a
notable period (n = 10), co-morbidity (n = 4), and
patients' refusal (n = 3).
The capsule findings, the subsequent procedures, and the
rebleeding rate after further intervention are summarized
in Table 3. The highest rate of rebleeding was seen in
patients with ulcers (31.2%) and angiodysplasia (30.8%).
Of the patients who were found to have an ulcer, the
rebleeding rate of the patients who did not undergo fur-
ther intervention was higher than that of those who did
undergo further intervention (p = 0.100). The patients
with angiodysplasia tended to develop clinical rebleeding
(50.0 %) despite endoscopic intervention, including cau-
tery. As expected, none of the patients who were found to
have a tumor and who underwent surgical intervention
subsequently developed rebleeding. Of the 7 patients with
bleeding without any identifiable lesions, 5 patients
underwent further procedures. Further examinations
resulted in diagnoses of small bowel angiodysplasia (n =
1), NSAIDs-related enteropathy (n = 1), hemosuccus pan-
creaticus (n = 1), colonic diverticula (n = 1), and
unknown (n = 1). Among them, rebleeding was observed
in 2 patients diagnosed with small bowel angiodysplasia
(endoscopic cautery was performed) and colonic divertic-
ula (an additional colonoscopy was performed), respec-
tively.
Table 1: Patient characteristics
n (%)
No. of patients 77
Gender (M/F) 54 (70.1)/23 (29.9)
Mean age, years ± SD 58.4 ± 18.4
Exam complete to colon 52 (67.5)
Bleeding (overt/occult) 60 (77.9)/17 (22.1)
Mean hemoglobin concentration, g/dl ± SD 7.7 ± 2.9
Mean follow-up period, months 11.6
Table 2: Findings of capsule endoscopy and rebleeding rate
Finding n Finding n
Significant Insignificant
Overall 45 (58.4%) Overall 32 (41.6%)
Ulcer 16 (35.6%) Erosion 16 (50.0%)
Angiodysplasia 13 (28.9%) Small ulcer 7 (21.9%)
Tumor 8 (17.8%) Red spot 3 (9.4%)
Bleeding without identifiable lesion 7 (15.6%) SMT/polyp 2 (6.3%)
Crohn's disease 1 (2.2%) Negative 4 (12.5%)
Note: SMT, submucosal tumorBMC Gastroenterology 2008, 8:12 http://www.biomedcentral.com/1471-230X/8/12
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Of the rebleeding cases, 4 patients in whom the source of
the rebleeding was detected during further examinations
had no small intestinal lesions. The sources of bleeding in
these patients were colonic diverticula (n = 2), gastric
angiodysplasia (n = 1), and hemosuccus pancreaticus (n =
1).
Discussion
The precise role of CE in the diagnostic algorithm of OGIB
has yet to be determined. Moreover, despite the higher
diagnostic yield of CE compared with other diagnostic
tools, the actual impacts of this examination on patient
outcome remain poorly defined. As CE itself is a purely
diagnostic modality, the improvements in bleeding
parameters cannot be directly attributed to CE. Instead, it
is likely that CE directs clinicians to the most appropriate
definitive therapy. If this therapy is effective, the rebleed-
ing rate of the patients ought to improve. We determined
the clinical outcome of patients with OGIB after CE using
the rebleeding rate as the primary outcome. Among the
patients with significant CE findings in this study, the
rebleeding rate of the patients who underwent therapeutic
intervention was significantly lower than that of those
who did not undergo intervention (9.5% vs 40.0%, p =
0.046). Thus, a clinically significant improvement was
seen among the patients with significant CE findings who
underwent therapeutic intervention. In previous reports,
the presence of significant CE findings was correlated with
rebleeding [15,16]. However, we proved that the rebleed-
ing rate of patients with significant CE findings was con-
siderably reduced with appropriate interventions after CE.
On the other hand, patients with insignificant CE findings
had a high rate of rebleeding during the follow-up period.
To say that the CE examination is not useful for these
patients with rebleeding was not overstating the case.
There are two main reasons why CE may be unable to
identify significant lesions. The first reason is that the CE
may miss a small intestinal lesion that accounts for the
bleeding. In our study, jejunal diverticula and a GI stro-
mal tumor were not visible on the CE images. Previous
studies have also reported that tumorous lesions were
missed during CE [17,18]. Moreover, we experienced two
cases in whom small intestinal ulcers were detected in the
distal part of the ileum using double-balloon enteros-
copy. The CE examinations had missed these lesions
because the capsules had not reached the cecum. Thus, the
CE findings were negative in these cases. In cases where
the CE results are negative but a high clinical suspicion of
a small bowel lesion remains, further examinations
should be considered. The second reason is that the
source of the bleeding may not exist in the small bowel
from outset. In this study, four patients with rebleeding,
in whom the source of the bleeding was detected during
further examinations did not have any small intestinal
lesions. The sources of bleeding in these patients were
colonic diverticula (n = 2), gastric angiodysplasia (n = 1),
and hemosuccus pancreaticus (n = 1). Thus, the source of
OGIB does not always originate in the small bowel.
The diagnostic yield of CE in patients with OGIB has been
described in previous reports [8,10,19-22]. The range of
the yields varies widely (31–92%) because of differences
in the definition of positive findings and the patient char-
acteristics. In the present study examining 77 patients, the
overall diagnostic yield was 58.4% for the significant find-
ings. Ulcers were the most common finding. This result
differed from that of many previous studies, in which
angiodysplasia was the most common finding [19,22,23].
Table 3: Rebleeding rate on follow-up procedures for significant capsule finding
Finding Endoscopic Surgical Radiographic Drug Without intervention Total
Overall 5/12 (41.7%) 0/9 (0%) 0/1 (0%) 1/8 (12.5%) 6/15 (40.0%) 12/45 (26.7%)
Ulcer 0/4 (0%) 0 0 1/5 (20.0%) 4/7 (57.1%) 5/16 (31.2%)
Angiodysplasia 2/4 (50.0%) 0/2 (0%) 0 0/1 (0%) 2/6 (33.3%) 4/13 (30.8%)
Tumor 1/1 (100%) 0/7 (0%) 0 0 0 1/8 (12.5%)
Bleeding without identifiable lesion 2/3 (66.7%) 0 0/1 (0%) 0/1 (0%) 0/2 (0%) 2/7 (28.6%)
Crohn's disease 0 0 0 0/1 (0%) 0 0/1 (0%)
Comparison of the rebleeding rates for each capsule finding  with or without intervention Figure 1
Comparison of the rebleeding rates for each capsule 
finding with or without intervention.BMC Gastroenterology 2008, 8:12 http://www.biomedcentral.com/1471-230X/8/12
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This discrepancy may be due to ethnical differences. Sev-
eral studies in Japanese populations have shown ulcers to
be the most common finding among small intestinal
lesions [24,25]. Ulcerations induced by the use of NSAIDs
typically resolve upon withdrawal of the medications in
most cases. In this study, only 1 of 4 patients developed
rebleeding. However, specific therapies have not been
established for nonspecific ulcers. Therefore, among these
cases, the rebleeding rate may be relatively high even
though the source of bleeding has been identified.
In this study, we evaluated the clinical impact of CE for
directing interventional therapy in patients with OGIB
and reported the long term results of this strategy using
the rebleeding rate as the primary outcome. This impor-
tant issue has been rarely studied to date; however, some
previous reports have described similar results. Recently,
Garcia-Compean et al. reported that a significantly
reduced rate of recurrent bleeding (6%) was observed in
patients with positive CE findings who underwent specific
treatment in a study of 40 patients with OGIB [26]. Del-
vaux et al. also reported similar results: among 18 patients
who were treated for intestinal lesions that were detected
by CE, only one patient (5%) relapsed during a 1 year fol-
low-up period [27]. Although the details of their treat-
ments were not exactly the same as ours, their results were
very similar. Moreover, when lesions observed at CE were
divided into highly relevant (P2) or less relevant (P0, P1)
according to the possibilities of their being responsible for
the GI bleeding, highly relevant lesions were more fre-
quently classified in true-positive cases and led more fre-
quently to therapeutic decisions, compared with less
relevant lesions [28]. The named P2 lesions proposed by
some authors correspond to significant findings of the
present study. These results suggest that this classification
of CE findings may assist clinicians in making appropriate
therapeutic decisions and may improve the clinical out-
come of patients with OGIB.
The selection of patients who underwent subsequent
interventions must be considered. Patients who had sig-
nificant co-morbidity and were on aspirin or anticoagu-
lants might have a high risk of rebleeding. In a recent
report, Sidhu et al. demonstrated that co-morbidity was a
significant predictive factor of a positive diagnostic yield
[26], and this result might be related to the rebleeding rate
in this patient population. However, in this study, only 1
of the 4 patients who had co-morbidities developed
rebleeding. Moreover, none of the patients did not
undergo therapeutic intervention because of co-morbidity
or the use of aspirin/anticoagulants. Therefore, co-mor-
bidity and the use of aspirin/anticoagulants did not affect
the decision to undergo intervention and were not associ-
ated with a high risk of rebleeding in this study. Further
CE studies are required to confirm these results.
This study has several limitations. First, this study was not
a randomized trial. Second, our results may be biased
because we tended to follow up our own patients more
accurately whereas the information from other hospitals
was often incomplete, probably because the referring phy-
sicians tended to inform us about their positive clinical
results only. Unfortunately, we could not evaluate the
hemoglobin values after intervention in this study. Third,
our study lacked objective criteria for performing the fol-
low-up examinations. A prospective study with objective
criteria is needed to determine the true efficacy of pursu-
ing further interventions after CE.
While swallowing disorders and pacemaker implantation
were regarded as exclusion criteria in the present study,
these factors are no longer regarded as contraindications
for the performance of CE. Actually, none of the patients
considered for enrollment in the present series had sus-
pected swallowing disorders or implanted pacemakers.
Conclusion
We evaluated the follow-up results of patients with OGIB
to determine which management strategies after CE
reduced rebleeding. The rebleeding rate was significantly
higher among patients with insignificant CE findings than
among those with significant CE findings. Among the
patients with significant CE findings, the rebleeding rate
of the patients who underwent therapeutic intervention
was significantly lower than that of those who did not
undergo intervention. Follow-up and further aggressive
interventions are necessary for patients with OGIB whose
CE findings are significant to reduce the chance of
rebleeding. Moreover, patients with insignificant CE find-
ings should undergo careful follow-up, keeping in mind
that the bleeding may not originate from within the small
bowel.
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